Global NewsNews

Global biosimilars market poised to reach $79.2 billion by 2026

The sector will grow at a CAGR of 17.3 per cent

Frost & Sullivan’s recent analysis, Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026, finds that the cost-benefit for end-users (patients) and ease of partnering with speciality contract development and manufacturing organisations (CDMOs) are driving the global biosimilars market. The third wave of biosimilars, with patent expiries from 2020 onward, is expected to hit the global market, covering complex biologic molecules like certain high-value mAbs and targeted therapies. 


The global biosimilars market is set to grow from $30.4 billion in 2020 to $79.2 billion by 2026 at a CAGR of 17.3 per cent. The third-wave biosimilars market is estimated to register staggering growth during the same period, reaching $5.46 billion by 2026 at an astounding 139.4 per cent compound annual growth rate (CAGR).

“With the onset of the third-wave biosimilars, partnerships and collaborations with CDMOs and other biopharmaceutical companies with exclusive commercial rights to markets will be the preferred business model in the biosimilars market. This will give companies improved access to new markets and enable higher market penetration,” said Deepak Jayakumar, Healthcare Industry Analyst, Frost & Sullivan. “The patent expiry of blockbuster biologics such as adalimumab, aflibercept, and ustekinumab in 2023 will result in the highest year-wise market revenue contribution from patent expiry.”

Jayakumar added, “From a drug-type perspective, while a large number of recombinant protein biologics are set for patent expiry between 2020 and 2026, the antibody therapy segment will have a higher cumulative market revenue as a higher number of blockbusters in the segment are set to lose their patent over the forecast period. Similarly, from the therapy area viewpoint, musculoskeletal, oncology, and immunomodulators will continue to generate high market revenues as they will be primarily driven by biosimilars. Sensory organs will be the highest revenue-generating segment among the newer therapy areas set to enter the market with the third wave of biosimilars.”

To benefit from the growth prospects exposed by the third wave of biosimilars, market participants need to focus on the following:

  • Provide real-world evidence (RWE) to substantiate the interchangeability claim. 
  • Collaborate with others and leverage novel discovery platforms. 
  • Expand the market base in different geographies, such as India, and understand domestic market dynamics. 
  • Accelerate the development of aflibercept and ranibizumab biosimilars and pre-register them before the biologics’ patent expiry to gain a first-to-market advantage.

Access to New Therapy Areas to Drive Major Growth in the Global Biosimilars Market, 2020–2026 is the latest addition to Frost & Sullivan’s Healthcare research and analyses available through the Frost & Sullivan Leadership Council, which helps organisations identify a continuous flow of growth opportunities to succeed in an unpredictable future.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.


Related Articles

Leave a Reply

Back to top button